Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)

Sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Study ID
NCT07556120
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Generalized Myasthenia Gravis

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • HN2301 injection — DRUG
    Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.

Study Details

This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.

Key Dates

First listed
Apr 29, 2026
Start date
May 5, 2026
Status verified
Apr 2026
Primary completion
May 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
6 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: HN2301 treatment group
    Participants will receive HN2301 Injection at the specified dose level and on the specified study days.

Primary Outcome Measure

Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 3 months ]

Central Contacts

Related Studies